Low RhoA expression is associated with adverse outcome in melanoma patients: a clinicopathological analysis.
RhoA
malignant melanoma
prognosis
survival
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
03
2019
accepted:
11
06
2019
entrez:
10
8
2019
pubmed:
10
8
2019
medline:
10
8
2019
Statut:
epublish
Résumé
RhoA GTPase is physiologically involved in the formation of stress fibers, cellular contractility and polarity, maintenance of cell cycle and transcriptional control. During tumorigenesis, it plays roles in cancer cell proliferation, apoptosis, adhesion, invasion and metastasis. While RhoA seems to act as a tumor promotor in most malignancies, data regarding its function in skin melanoma are fragmentary and conflicting. We aimed to clarify the clinical significance of RhoA expression in melanoma by immunohistochemical evaluation of 134 primary tumors and subsequent statistical analysis with clinicopathological profiles of patients. Increased RhoA expression was associated with thinner tumors, higher grade of tumor-infiltrating lymphocytes and lack of disease recurrence. Moreover, we observed a trend towards higher RhoA expression in cases without concurrent metastases. Recurrence-free survival and melanoma-specific survival of patients with high RhoA-expressing tumors were significantly prolonged. Multivariable regression model adjusting for melanoma thickness and status of regional lymph nodes confirmed independent prognostic value of RhoA immunoreactivity. In summary, we found associations between RhoA expression and histopathological phenotype of primary tumors as well as patient survival which suggest a suppressive role of RhoA in skin melanoma.
Types de publication
Journal Article
Langues
eng
Pagination
4524-4532Déclaration de conflit d'intérêts
None.
Références
Exp Cell Res. 1999 Nov 25;253(1):166-79
pubmed: 10579921
Ann N Y Acad Sci. 2000 Apr;905:301-7
pubmed: 10818470
Mol Biol Cell. 2001 Jan;12(1):27-36
pubmed: 11160820
Mol Biol Cell. 2002 Mar;13(3):902-14
pubmed: 11907271
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15548-53
pubmed: 14657354
Mol Ther. 2005 Feb;11(2):267-74
pubmed: 15668138
Annu Rev Cell Dev Biol. 2005;21:247-69
pubmed: 16212495
Cancer Res. 2005 Dec 1;65(23):10938-45
pubmed: 16322241
Biol Pharm Bull. 2006 Nov;29(11):2256-9
pubmed: 17077524
Neoplasia. 2007 Dec;9(12):1078-90
pubmed: 18084615
Eur J Cancer. 2008 Jul;44(11):1587-95
pubmed: 18495474
Biochim Biophys Acta. 2009 Dec;1796(2):91-8
pubmed: 19327386
Oncol Rep. 2010 Mar;23(3):861-7
pubmed: 20127030
Front Biosci (Landmark Ed). 2011 Jan 01;16:1915-26
pubmed: 21196273
Cancer Res. 2011 May 1;71(9):3246-56
pubmed: 21430067
Mol Cancer. 2011 Sep 14;10:114
pubmed: 21917148
Cell Biol Int. 2012 Mar 1;36(3):311-9
pubmed: 22070397
Hepatogastroenterology. 2012 Nov-Dec;59(120):2523-6
pubmed: 22584506
FEBS Lett. 2012 Jul 4;586(14):1959-70
pubmed: 22710176
Ann Dermatol. 2013 May;25(2):135-44
pubmed: 23717002
Cell Signal. 2014 Mar;26(3):461-7
pubmed: 24316235
Nat Commun. 2014 Nov 21;5:5458
pubmed: 25413277
Front Oncol. 2015 Feb 13;5:31
pubmed: 25763355
Br J Cancer. 2016 Jan 12;114(1):63-70
pubmed: 26671750
Oxid Med Cell Longev. 2016;2016:2696952
pubmed: 26823948
PLoS One. 2016 Feb 01;11(2):e0148095
pubmed: 26828592
Small GTPases. 2016 Jul 2;7(3):123-38
pubmed: 27104658
BMC Cancer. 2016 Aug 22;16:667
pubmed: 27549189
Small GTPases. 2016 Oct;7(4):207-221
pubmed: 27628050
J Cell Physiol. 2018 Sep;233(9):6381-6392
pubmed: 29377108
Cell Rep. 2018 Sep 18;24(12):3224-3236
pubmed: 30232004
Transl Res. 2019 Feb;204:72-81
pubmed: 30342000
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008